Piper Sandler last night upgraded Sutro Biopharma (STRO) to Overweight from Neutral with an unchanged price target of $2. The company plans to file three new drug applications on next-generation antibody-drug conjugates over the next three years, the analyst tells investors in a research note. The firm says Sutro ended Q1 with cash of $249M to fund operations into 2027 and currently trades at a negative $181M enterprise value. Piper sees an attractive valuation at current share levels.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STRO: